DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2006/0178307 A1 Bartlett Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2006/0178307 A1 Bartlett Et Al US 2006O1783 07A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0178307 A1 Bartlett et al. (43) Pub. Date: Aug. 10, 2006 (54) MODULATION OF NMDA RECEPTOR Publication Classification CURRENTS VIA OREXN RECEPTOR AND/OR CRF RECEPTOR (51) Int. Cl. A6II 38/22 (2006.01) (75) Inventors: Selena Bartlett, Berkeley, CA (US); A6II 3L/495 (2006.01) Antonello Bonci, San Francisco, CA A61K 31/4745 (2006.01) (US); Stephanie Borgland, San A61K 31/4706 (2006.01) Francisco, CA (US); Howard Fields, A6II 3/17 (2006.01) Berkeley, CA (US); Sharif Taha, (52) U.S. Cl. ...................... 514/12: 514/255.01: 514/300; Berkeley, CA (US) 514/313; 514/585; 514/595 (57) ABSTRACT Correspondence Address: QUINE INTELLECTUAL PROPERTY LAW This invention pertains to the discoveries that orexin and/or GROUP, PC. CRF increase NMDAR (N-methyl-D-aspartate receptor)- PO BOX 458 mediated currents at excitatory synapses onto a Subset of dopamine cells in the ventral tegmental area (VTA) in the ALAMEDA, CA 94501 (US) mammalian brain. The orexin effect can be blocked by an (73) Assignee: The Regents of the University of Cali orexin receptor type 1 (OXR1). The CRF effect can be blocked by a CRF receptor 2 (CRF-R2) antagonist or by an fornia inhibitor of the CRF-binding protein (CRF-BP). Methods (21) Appl. No.: 11/343,259 are provided that exploit these discoveries to modulate NMDAR-mediated currents in vivo and in vitro and to (22) Filed: Jan. 25, 2006 screen for modulators (upregulators or downregulators) of NMDA-mediated currents. In vivo methods include the use Related U.S. Application Data of modulators of the orexin and CRF pathways to of mitigate a symptom of Substance abuse. The invention also provides (60) Provisional application No. 60/647,748, filed on Jan. methods and compositions for co-administration of modu 26, 2005. lators that act via the orexin and CRF pathways. Patent Application Publication Aug. 10, 2006 Sheet 1 of 14 US 2006/0178307 A1 4. 200 150 00 SO O O 10 20 30 40 50 60 10 100 Time (nin) Orexin A nM 00 75 100 nM orexin A F 1 M SB 334867 50 25 O 10 20 30 4. 50 SO O 10 20 30 40 60 Time (min) Tine (nir) F Biocytin-TR H-FITC Merge 200 75 150 125 100 7 5 100 nM orexin A 0 10 20 30 40 50 60 70 80 Time (min) Fig. 1 Patent Application Publication Aug. 10, 2006 Sheet 2 of 14 US 2006/0178307 A1 A B C g M chellerythrin 1M U73122 ia. ia. S. so 100 sissiliig, g a. 50 0 exi A : g e n 2 in s 2 3 4 so SO 70 O 1. 3. O S. Time (min) Time (min) Tirna (min) D F 100 Mrp-cAMPS 20 all PKI 3. s sis g Oncrek A Y 5 a. e a 2 to so 3 S 6 Tirne trir) line (min) Tim a min) Fig. 2 Patent Application Publication Aug. 10, 2006 Sheet 3 of 14 US 2006/0178307 A1 A B 0.4 MNVP-AAMO77 20 15 o 100 nM orexin a Ho 0.4 MNVP-AAM077 O O 20 30 40 50 60 O 10 20 30 40 50 60 Ting (nir Tine (rnin} C. D o 3 Mifeprodil 150 Eo 125 Zn M 25 100 AM. 300 nM 100 """"" SS 0.O a 75 7s 50 E 10 nM orexin A 00 nMorexin A e c a s 0 10 20 30 4 SO SO 70 80 a Time (min) Time (min) E as 0.4 MNVP-AAMO77 28 0.4 MNVF. AAM077 E 1 25 s 3 Mifenprodil d 3 Miferprodil e R d 100 100 1 MPPDA s s a 75 a 75 100 nM orexin A a. 50 So 25 25 a S O O 10 20 30 40 50 50 2s 0 0 20 30 40 50 60 70 80 Time (min) Time (min) Fig. 3 Patent Application Publication Aug. 10, 2006 Sheet 4 of 14 US 2006/0178307 A1 A - - - - - - - - B no statio C on no stimulation 10 Mt. K-801 O mR as 10 am MK-8O1 S. 20 P g r St s 15 3. Es 1. e E e so e s 2 a 1 20 so a so is 70 Time (min) Time (min) C D hostinator an PO nostitulation 2 S 20 it MMK-8 + 500 MNLA SO o P g 10 MMK-801 + 500 M MMDA 1 wwat M s g 100 E s 50 2 5 e 100 nM orexin A. s 2 0 20 30 O 20 30 40 50 so 70 Time (min) Time (min) Fig. 4 Patent Application Publication Aug. 10, 2006 Sheet 5 of 14 US 2006/0178307 A1 A COCaine COCaine + SB 334867 1.O. S. O.8 O O.6 s2 O. 5. 0.2 g O. saline cocaine saline cocaine SB 334867 B Control 15 min 3-4 hours 1,O O. 2 O, O control 5 in 3-4 hours Fig. 5 Patent Application Publication Aug. 10, 2006 Sheet 6 of 14 US 2006/0178307 A1 Control 15 min 3-4 hours control 15 min 3-4 hours APW control 15 mr 3-4 hours APW 1.0 1. 0. 2. t r al a coffo al m C. to s 0.5 15 min S. 0.5 -w 15 mi s wim 3-4 hours -3-4 hours m 3-4 hours + APW 2 -a 3-hours 4 APW U , 0. 0 10 20 so 40 50 60 O 2 3 4. S 6 nEFSC Amplitude (pA) inter-evont linterval (s) H Time (min) 2.5 5.0 75 100 e (min) 0- it S-100 -200 c .300 Patent Application Publication Aug. 10, 2006 Sheet 7 of 14 US 2006/0178307 A1 Control 15 in 3-4 hours D E g m St 3 g es s . e le; : 3 3 l E E e O contro 1S in 3-4 hours contro Smin 3-4 ours F G 1, 1. cer e . o d - control 0.5 it. g 0.5 or 15 min reme as ours s -o-, 3-4 hours are sE w . 0. 1. 2. O 40 1 2 s 4. H mEPSC Amplitudo pa) inter-event intervals 400 300 k 2 20 100 e s. s Time (min) Time (min) Patent Application Publication Aug. 10, 2006 Sheet 8 of 14 US 2006/0178307 A1 -- cocaine + wahicle -- cocaine + SB 334867 soooo-o-Safine * Wehicle 40000 -e-saline + S8 334867 9. 5 3000 g s Cs i 20000 8 is 100 t O 0 1 2 3 4 s 6 7 8 Days C D 70000 ama 6000 5 5000 40000 au h 3000 2 20000 s amb 0-F 10000 0. Oay 1 Day 7 day 1 day 7 tra-WA Wuicle intra-WTASB 334867 Patent Application Publication Aug. 10, 2006 Sheet 9 of 14 US 2006/0178307 A1 0.75 0.50 0.25 Fig. 9 Patent Application Publication Aug. 10, 2006 Sheet 10 of 14 US 2006/0178307 A1 Patent Application Publication Aug. 10, 2006 Sheet 11 of 14 US 2006/0178307 A1 300 Naive Vehicle Vehicle S334867 Naive Wehicle Weice SB 33436 25 20 1o s O Naive Weice Wehicle SB3348S Naive Wehicle Weice S333,867 Fig. 11 Patent Application Publication Aug. 10, 2006 Sheet 12 of 14 US 2006/0178307 A1 A B 7 6 on 5 8 3 s - 2 O Vehicle Vehicle SB334867 Naive Wehicle Vehicle SB334867 200 10 O Vehicle Vehicle S8334367 Naive Vehicle Vehicle S3334867 Fig. 12 Patent Application Publication Aug. 10, 2006 Sheet 13 of 14 US 2006/0178307 A1 0.01 0 1 1.0 CRF concentration (M) Fig. 13 Patent Application Publication Aug. 10, 2006 Sheet 14 of 14 US 2006/0178307 A1 A B as S 50 5 40 3. S. St 3 30 ()2 20 C. 2 C 10 Ze 0 1 10 100 Orexin A nM Time (min) C D 225 g 150 125 s 175176 3 is 100 125- Yua d 75 1 nM orexin A is 75 al 50 10 nM CRF 1 nM orexin A 25 1OM CRF a 25 O o 20 30 40 50 SO O 10 20 30 40 50 SO Time (min) Time (min) Fig. 14 US 2006/0178307 A1 Aug. 10, 2006 MODULATION OF NMDA RECEPTOR CURRENTS abuse and plays a key role in stress-induced relapse to drug VIA OREXIN RECEPTOR AND/OR CRF taking (Sarnyai et al. (2001) Pharmacol. Rev. 53: 209-243). RECEPTOR The cellular effects of CRF are mediated via two receptors (CRF-R1 and CRF-R2) (Dautzenberg and Hauger (2002) CROSS-REFERENCE TO RELATED Trends Pharmacol. Sci. 23, 71-77); CRF also binds to a APPLICATIONS binding protein (CRF-BP), which is thought to inactivate 0001) This application claims the benefit of U.S. Provi free CRF (Kemp et al. (1998) Peptides 19: 1119-1128). It sional Application No. 60/647,748, filed Jan. 26, 2005, has been suggested that CRF-BP inhibitors, which elevate which is hereby incorporated by reference in its entirety. free CRF levels, may provide potential treatments for disorders where CRF levels are depressed, such as Alzhe STATEMENT AS TO RIGHTS TO INVENTIONS imer's disease and Parkinson's disease (Behan et al. (1995) MADE UNDER FEDERALLY SPONSORED Nature 378: 284-287). It is notable that many of these RESEARCH AND DEVELOPMENT disorders involving elevated CRF levels are also thought to involve elevated dopamine levels and that CRF increases 0002 This invention was made with government support dopamine release in both limbic and cortical projection areas under grant no.
Load more

Recommended publications
  • NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function
    NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function Tommy Weiss Sadan, Ph.D. and Melanie R. Grably, Ph.D. N-Methyl-D-Aspartate Receptor (NMDAR) are ubiquitously expressed along the central nervous system and are instrumental to various physiological processes such as synaptic plasticity and learning. Nevertheless, several mental disabilities including schizophrenia and Alzheimer’s disease are all related to NMDAR dysfunction. Here, we review many aspects of NMDAR function and regulation and describe their involvement in pathophysiological states using Alomone Labs products. Right: Cell surface detection of GluN2B in rat hippocampal neurons. Introduction Mechanism of Action Glutamate is a key neuro-transmitter in the central nervous system and NMDAR activation depends on sequential conformational changes to acts on a variety of cell surface receptors, collectively termed ionotropic relieve the magnesium blockade which is achieved by rapid membrane glutamate receptors (iGluRs)15. The N-Methyl-D-Aspartate receptors (NMDAR) depolarization and binding of both glycine and glutamate ligands6, 21. This in are members of the iGluR superfamily and are pivotal to many physiological turn removes the inhibitory electrostatic forces of magnesium and enables processes such as the formation of long term memory, synaptic plasticity calcium influx and transmission of long lasting signals (i.e. long-term and many other cognitive functions. Therefore, it is not surprising that potentiation), a key mechanism to learning and memory formation10.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun
    USOO8748131B2 (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun. 10, 2014 (54) CHIMERIC NEUREGULINS AND METHOD in Neuregulin-1/ErbB Signaling. The Journal of Biological Chemis OF MAKING AND USE THEREOF try vol. 285, No. 41, pp. 31388-31398, Oct. 8, 2010.* Veronese et al., PEGylation. Successful approach to drug delivery. (71) Applicant: Morehouse School of Medicine, Drug Discovery Today vol. 10, No. 21 Nov. 2005, 1451-1458.* Atlanta, GA (US) Carraway et al., Neuregulin-2, a new ligand ErbB3/ErbB4-receptor tyrosine kinases. Nature, vol. 387, May 29, 1997, 512-516.* (72) Inventor: Byron D. Ford, Atlanta, GA (US) Higashiyamaet al., ANovel Brain-Derived Member of the Epidermal Growth Factor Family That Interacts with ErbB3 and ErbB4. J. (73) Assignee: Morehouse School of Medicine, Biochem. 122,675-680 (1997).* Atlanta, GA (US) Fischbach et al., “ARIA: A Neuromuscular Junction Neuregulin.” Annual Review of Neuroscience, 1997, pp. 429–458, vol. 20. (*) Notice: Subject to any disclaimer, the term of this Buonanno et al., “Neuregulin and ErbB receptor signaling pathways patent is extended or adjusted under 35 in the nervous system.” Current Opinion in Neurobiology, 2001, pp. U.S.C. 154(b) by 0 days. 287-296, vol. 11. Burden et al., “Neuregulins and Their Receptors: A Versatile Signal Appl. No.: 13/627,555 ing Module in Organogenesis and Oncogenesis. Neuron, 1997, pp. (21) 847-855, vol. 18. Fu et al., “Cdk5 is involved in neuregulin-induced AChR expression (22) Filed: Sep. 26, 2012 at the neuromuscular junction.” Nature Neuroscience, Apr.
    [Show full text]
  • JPET #82990 Identification of Subunit-Specific and Antagonist
    JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 JPET ThisFast article Forward. has not been Published copyedited onand formatted.March 2, The 2005 final versionas DOI:10.1124/jpet.104.082990 may differ from this version. JPET #82990 Identification of subunit-specific and antagonist-specific amino acid residues in the NMDA receptor glutamate binding pocket Downloaded from Leo Kinarsky1, Bihua Feng1, Donald A. Skifter, Richard M. Morley, Simon Sherman, jpet.aspetjournals.org David E. Jane, and Daniel Monaghan. 1The Eppley Research Institute (L.K., S.S.) and the Department of Pharmacology (B.F., D.A.S., D.T.M.) University of Nebraska Medical Center; and Department of Pharmacology, University of Bristol, Bristol, U.K. (R.M.M., at ASPET Journals on September 26, 2021 D.E.J.). 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 This article has not been copyedited and formatted. The final version may differ from this version. JPET #82990 Running title: NR2 glutamate binding site models Correspondence: Downloaded from Daniel T. Monaghan, Ph.D. Department of Pharmacology 985800 Nebraska Medical Center jpet.aspetjournals.org Omaha, NE 68198-5800 402-559-7196, FAX: 402-559-7495, e-mail: [email protected] at ASPET Journals on September 26, 2021 Pages: 19 Tables: 0 Figures: 6 References: 40 Number of words Abstract: 243 Introduction: 607 Discussion: 1369 2 JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 This article has not been copyedited and formatted.
    [Show full text]
  • A Review of Glutamate Receptors I: Current Understanding of Their Biology
    J Toxicol Pathol 2008; 21: 25–51 Review A Review of Glutamate Receptors I: Current Understanding of Their Biology Colin G. Rousseaux1 1Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Abstract: Seventy years ago it was discovered that glutamate is abundant in the brain and that it plays a central role in brain metabolism. However, it took the scientific community a long time to realize that glutamate also acts as a neurotransmitter. Glutamate is an amino acid and brain tissue contains as much as 5 – 15 mM glutamate per kg depending on the region, which is more than of any other amino acid. The main motivation for the ongoing research on glutamate is due to the role of glutamate in the signal transduction in the nervous systems of apparently all complex living organisms, including man. Glutamate is considered to be the major mediator of excitatory signals in the mammalian central nervous system and is involved in most aspects of normal brain function including cognition, memory and learning. In this review, the basic biology of the excitatory amino acids glutamate, glutamate receptors, GABA, and glycine will first be explored. In the second part of this review, the known pathophysiology and pathology will be described. (J Toxicol Pathol 2008; 21: 25–51) Key words: glutamate, glycine, GABA, glutamate receptors, ionotropic, metabotropic, NMDA, AMPA, review Introduction and Overview glycine), peptides (vasopressin, somatostatin, neurotensin, etc.), and monoamines (norepinephrine, dopamine and In the first decades of the 20th century, research into the serotonin) plus acetylcholine. chemical mediation of the “autonomous” (autonomic) Glutamatergic synaptic transmission in the mammalian nervous system (ANS) was an area that received much central nervous system (CNS) was slowly established over a research activity.
    [Show full text]
  • Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation
    The Journal of Neuroscience, July 20, 2005 • 25(29):6907–6910 • 6907 Brief Communication Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation Sven Berberich,1* Pradeep Punnakkal,1* Vidar Jensen,2 Verena Pawlak,1 Peter H. Seeburg,1 Øivind Hvalby,2 and Georg Ko¨hr1 1Department of Molecular Neurobiology, Max-Planck-Institute for Medical Research, D-69120 Heidelberg, Germany, and 2Molecular Neurobiology Research Group, Institute of Basic Medical Sciences, University of Oslo, N-0317 Oslo, Norway NMDA receptor (NMDAR) 2A (NR2A)- and NR2B-type NMDARs coexist in synapses of CA1 pyramidal cells. Recent studies using pharmacological blockade of NMDAR subtypes proposed that the NR2A type is responsible for inducing long-term potentiation (LTP), whereas the NR2B type induces long-term depression (LTD). This contrasts with the finding in genetically modified mice that NR2B-type NMDARs induce LTP when NR2A signaling is absent or impaired, although compensatory mechanisms might have contributed to this result. We therefore assessed the contribution of the two NMDAR subtypes to LTP in mouse hippocampal slices by different induction protocols and in the presence of NMDAR antagonists, including the NR2A-type blocker NVP-AAM077, for which an optimal concentra- tion for subtype selectivity was determined on recombinant and native NMDARs. Partial blockade of NMDA EPSCs by 40%, either by preferentially antagonizing NR2A- or NR2B-type NMDARs or by the nonselective antagonist D-AP-5, did not impair LTP, demonstrating that hippocampal LTP induction can be generated by either NMDAR subtype. Key words: NVP-AAM077; PEAQX; CP-101,606; recombinant; gene-targeted mouse; partial blockade; pairing Introduction Materials and Methods During postnatal development, the hippocampal signaling cas- Recombinant receptors.
    [Show full text]
  • Antidepresszánsok Nem Konvencionális Hatásai a Központi És Perifériás Idegrendszerben
    Antidepresszánsok nem konvencionális hatásai a központi és perifériás idegrendszerben Doktori értekezés Dr. Mayer Aliz Semmelweis Egyetem Szentágothai János Idegtudományi Doktori Iskola Témavezet ő: Dr. Kiss János, Ph.D. Hivatalos bírálók: Dr. Köles László egyetemi adjunktus, Ph.D. Dr. K őfalvi Attila tudományos f őmunkatárs, Ph.D. Szigorlati bizottság elnöke: Dr. Kecskeméti Valéria egyetemi tanár, az orvostudományok kandidátusa Szigorlati bizottság tagjai: Dr. Hársing László Gábor tudományos tanácsadó, az MTA doktora Dr. Tretter László, egyetemi docens, az orvostudományok kandidátusa Budapest 2009 TARTALOMJEGYZÉK 1. Rövidítések jegyzéke………………………………………………………………....3 2. Bevezetés…………………………………………………………………………...…4 3. Irodalmi háttér és el őzetes eredmények………………………………………........6 3.1. A monoamin teória és egyéb, alternatív depresszió-teóriák……………......……….6 3.2. Antidepresszánsok…………………………………………………………..………8 3.3. Antidepresszánsok hatása a központi idegrendszer nAChR-aira………………….11 3.4. A nAChR-ok és a monoamin transzporterek közös sajátságai ………………….....15 3.4.1. A központi idegrendszer nikotinos acetilkolin receptorai (nAChR)..............15 3.4.2. A monoamin transzporterek jellemz ői................….……………….……….18 3.5. Az ionotróp receptorok általános áttekintése …………………...............................21 4. Célkit űzések…………………………………………………………...……………36 5. Módszerek………………………………………………………………..…………38 5.1. In vitro szeletperfúziós technika……………………………………….....……......38 5.1.1. Tríciált noradrenalin [ 3H]NA felszabadulás mérése patkány hippokampusz
    [Show full text]
  • Orally Active Compound Library (96-Well)
    • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Orally Active Compound Library (96-well) Product Details: Catalog Number: CS-L061 Formulation: A collection of 2244 orally active compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L061-1 1 2 3 4 5 6 7 8 9 10 11 12 a Empty Vonoprazan Mivebresib AZD0156 BAY-876 Tomivosertib PQR620 NPS-2143 R547 PAP-1 Delpazolid Empty Varenicline b Empty Varenicline (Hydrochlorid Varenicline A-205804 CI-1044 KW-8232 GSK583 Quiflapon MRK-016 Diroximel Empty e) (Tartrate) fumarate SHP099 c Empty A 922500 SHP099 (hydrochlorid Nevanimibe Pactimibe Pactimibe GNF-6231 MLi-2 KDM5-IN-1 PACMA 31 Empty e) hydrochloride (sulfate) Rilmenidine d Empty Cadazolid Treprostinil GSK3179106 Esaxerenone (hemifumarat Rilmenidine Fisogatinib BP-1-102 Avadomide Aprepitant Empty e) (phosphate) Cl-amidine AZD5153 (6- e Empty Maropitant Abscisic acid (hydrochlorid BGG463 WNK463 Ticagrelor Axitinib Hydroxy-2- CGS 15943 Pipamperone Empty e) naphthoic Setogepram Teglarinad f Empty Y-27632 GSK2193874 Lanabecestat CXD101 Ritlecitinib YL0919 PCC0208009 (sodium salt) (chloride) Futibatinib Empty TAK-659 g Empty NCB-0846 GS-444217 (hydrochlorid Navitoclax ABX464 Zibotentan Simurosertib (R)- CEP-40783 MK-8617 Empty e) Simurosertib Choline JNJ- h Empty CCT251236 (bitartrate) Sarcosine Brensocatib AS-605240 PF-06840003
    [Show full text]
  • Reconsolidation Blockade for the Treatment of Addiction: Challenges, New Targets, and Opportunities
    Downloaded from learnmem.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Review Reconsolidation blockade for the treatment of addiction: challenges, new targets, and opportunities Marc T.J. Exton-McGuinness1 and Amy L. Milton2 1School of Psychology, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom; 2Department of Psychology, University of Cambridge, Downing Site, Cambridge CB2 3EB, United Kingdom Addiction is a chronic, relapsing disorder. The progression to pathological drug-seeking is thought to be driven by mal- adaptive learning processes which store and maintain associative memory, linking drug highs with cues and actions in the environment. These memories can encode Pavlovian associations which link predictive stimuli (e.g., people, places, and paraphernalia) with a hedonic drug high, as well as instrumental learning about the actions required to obtain drug-associated incentives. Learned memories are not permanent however, and much recent interest has been generated in exploiting the process of reconsolidation to erase or significantly weaken maladaptive memories to treat several mental health disorders, including addictions. Normally reconsolidation serves to update and maintain the adaptive rele- vance of memories, however administration of amnestic agents within the critical “reconsolidation window” can weaken or even erase maladaptive memories. Here we discuss recent advances in the field, including ongoing efforts to translate pre- clinical reconsolidation research in animal models into clinical practice. Addiction is a complex disorder believed to be driven by many dys- cues in precipitating relapse in animal models (Bossert et al. 2013), functional psychological and neurobiological factors. One pro- as well as activating corticostriatal-limbic reward circuitry (for re- minent account suggests that pathological learning mechanisms view, see Jasinska et al.
    [Show full text]
  • Structural Basis of Subunit Selectivity for Competitive NMDA Receptor Antagonists with Preference for Glun2a Over Glun2b Subunits
    Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits Genevieve E. Linda,b, Tung-Chung Moub,c, Lucia Tamborinid, Martin G. Pompere, Carlo De Michelid, Paola Contid, Andrea Pintof,1, and Kasper B. Hansena,b,1 aDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812; bCenter for Biomolecular Structure and Dynamics, University of Montana, Missoula, MT 59812; cDivision of Biological Sciences, University of Montana, Missoula, MT 59812; dDepartment of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy; eRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical School, Baltimore, MD 21205; and fDepartment of Food, Environmental and Nutritional Science, University of Milan, 20133 Milan, Italy Edited by Richard W. Aldrich, The University of Texas at Austin, Austin, TX, and approved July 5, 2017 (received for review May 10, 2017) NMDA-type glutamate receptors are ligand-gated ion channels that Considerable progress has been made in the development of contribute to excitatory neurotransmission in the central nervous subunit-selective allosteric modulators (7–13), but the development system (CNS). Most NMDA receptors comprise two glycine-binding of subtype-selective competitive NMDA receptor antagonists has GluN1 and two glutamate-binding GluN2 subunits (GluN2A–D). We been less successful. The competitive glutamate-site antagonist describe highly potent (S)-5-[(R)-2-amino-2-carboxyethyl]-4,5-dihy- NVP-AAM077 (hereafter NVP) was originally reported to have dro-1H-pyrazole-3-carboxylic acid (ACEPC) competitive GluN2 antag- 100-fold preference for GluN1/2A over GluN1/2B (14). As such, onists, of which ST3 has a binding affinity of 52 nM at GluN1/2A and this compound has been extensively used to investigate the role of 782 nM at GluN1/2B receptors.
    [Show full text]
  • Review Article Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies
    Hindawi Publishing Corporation Neural Plasticity Volume 2016, Article ID 2701526, 20 pages http://dx.doi.org/10.1155/2016/2701526 Review Article Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies Francisco J. Carvajal,1 Hayley A. Mattison,2 and Waldo Cerpa1 1 Laboratorio de Funcion´ y Patolog´ıa Neuronal, Departamento de Biolog´ıa Celular y Molecular, Facultad de Ciencias Biologicas,´ Pontificia Universidad CatolicadeChile,8331150Santiago,Chile´ 2Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA Correspondence should be addressed to Waldo Cerpa; [email protected] Received 19 February 2016; Revised 13 June 2016; Accepted 29 June 2016 Academic Editor: Kui D. Kang Copyright © 2016 Francisco J. Carvajal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. N-Methyl-D-aspartate receptors (NMDARs) have two opposing roles in the brain. On the one hand, NMDARs control critical events in the formation and development of synaptic organization and synaptic plasticity. On the other hand, the overactivation 2+ of NMDARs can promote neuronal death in neuropathological conditions. Ca influx acts as a primary modulator after NMDAR 2+ channel activation. An imbalance in Ca homeostasis is associated with several neurological diseases including schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. These chronic conditions have a lengthy progression depending on internal and external factors. External factors such as acute episodes of brain damage are associated with an earlier onset of several of these chronic mental conditions.
    [Show full text]
  • Extrasynaptic NMDA Receptors on Rod Pathway Amacrine Cells: Molecular Composition, Activation, and Signaling
    The Journal of Neuroscience, January 23, 2019 • 39(4):627–650 • 627 Cellular/Molecular Extrasynaptic NMDA Receptors on Rod Pathway Amacrine Cells: Molecular Composition, Activation, and Signaling X Margaret L. Veruki,1 Yifan Zhou,1 A´urea Castilho,1 XCatherine W. Morgans,2 and XEspen Hartveit1 1University of Bergen, Department of Biomedicine, N-5009 Bergen, Norway, and 2Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon 97239 In the rod pathway of the mammalian retina, axon terminals of glutamatergic rod bipolar cells are presynaptic to AII and A17 amacrine cells in the inner plexiform layer. Recent evidence suggests that both amacrines express NMDA receptors, raising questions concerning molecular composition, localization, activation, and function of these receptors. Using dual patch-clamp recording from synaptically connected rod bipolar and AII or A17 amacrine cells in retinal slices from female rats, we found no evidence that NMDA receptors contribute to postsynaptic currents evoked in either amacrine. Instead, NMDA receptors on both amacrine cells were activated by ambient glutamate, and blocking glutamate uptake increased their level of activation. NMDA receptor activation also increased the frequency of GABAergic postsynaptic currents in rod bipolar cells, suggesting that NMDA receptors can drive release of GABA from A17 amacrines. A striking dichotomy was revealed by pharmacological and immunolabeling experiments, which found GluN2B-containing NMDA receptors on AII amacrines and GluN2A-containing NMDA receptors on A17 amacrines. Immunolabeling also revealed a clus- tered organization of NMDA receptors on both amacrines and a close spatial association between GluN2B subunits and connexin 36 on AII amacrines, suggesting that NMDA receptor modulation of gap junction coupling between these cells involves the GluN2B subunit.
    [Show full text]
  • Contribution of an SFK-Mediated Signaling Pathway in the Dorsal Hippocampus to Cocaine-Memory Reconsolidation in Rats
    Neuropsychopharmacology (2016) 41, 675–685 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org Contribution of an SFK-Mediated Signaling Pathway in the Dorsal Hippocampus to Cocaine-Memory Reconsolidation in Rats 1 2 3 3 4 4 Audrey M Wells , Xiaohu Xie , Jessica A Higginbotham , Amy A Arguello , Kati L Healey , Megan Blanton and Rita A Fuchs*,3 1 2 Behavioral Genetics Laboratory, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, CA, USA; Department of 3 Chemistry, North Carolina State University, Raleigh, NC, USA; Department of Integrative Physiology and Neuroscience, Washington State University College of Veterinary Medicine, Pullman, WA, USA; 4Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA – – Environmentally induced relapse to cocaine seeking requires the retrieval of context response cocaine associative memories. These memories become labile when retrieved and must undergo reconsolidation into long-term memory storage to be maintained. Identification of the molecular underpinnings of cocaine-memory reconsolidation will likely facilitate the development of treatments that mitigate the impact of cocaine memories on relapse vulnerability. Here, we used the rat extinction-reinstatement procedure to test the hypothesis that the Src family of tyrosine kinases (SFK) in the dorsal hippocampus (DH) critically controls contextual cocaine-memory reconsolidation. To μ this end, we evaluated the effects of bilateral intra-DH microinfusions of the SFK inhibitor, PP2 (62.5 ng per 0.5 l per hemisphere), following re-exposure to a cocaine-associated (cocaine-memory reactivation) or an unpaired context (no memory reactivation) on subsequent drug context-induced instrumental cocaine-seeking behavior.
    [Show full text]